ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$9M
5Y Perf.-98.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASBP vs XXII
Revenue, margins, valuation, and 5-year total return — side by side.
XXII
22nd Century Group, Inc.
Tobacco
Market Cap$621K
5Y Perf.-99.9%
ASBP vs XXII — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | XXII |
|---|---|---|
| Industry | Biotechnology | Tobacco |
| Market Cap | $9M | $621K |
| Revenue (TTM) | $2K | $10M |
| Net Income (TTM) | $-32M | $-7M |
| Gross Margin | 45.5% | -34.3% |
| Operating Margin | -10314.4% | -124.1% |
| Total Debt | $1M | $9M |
| Cash & Equiv. | $4K | $4M |
ASBP vs XXII — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
XXII
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.4 | -98.6% |
| 22nd Century Group,… (XXII) | 100 | 0.1 | -99.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs XXII
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XXII leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aspire Biopharma Holdings, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ASBP
Aspire Biopharma Holdings, Inc.
The Long-Run Compounder
ASBP is the clearest fit if your priority is long-term compounding.
- -98.4% 10Y total return vs XXII's -100.0%
- -49.7% vs XXII's -99.8%
Best for: long-term compounding
XXII
22nd Century Group, Inc.
The Income Pick
XXII carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.60, yield 100.0%
- Lower volatility, beta 1.60, current ratio 1.16x
- Beta 1.60, yield 100.0%, current ratio 1.16x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XXII | -63.1% revenue growth vs ASBP's -13.7% |
| Quality / Margins | XXII | -65.7% margin vs ASBP's -16K% |
| Stability / Safety | XXII | Beta 1.60 vs ASBP's 1.74 |
| Dividends | XXII | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | ASBP | -49.7% vs XXII's -99.8% |
| Efficiency (ROA) | XXII | -27.8% ROA vs ASBP's -13.2% |
ASBP vs XXII — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ASBP vs XXII — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXXIILAGGINGASBP
ASBPAspire Biopharma Hold…
1leads
XXII22nd Century Group, I…
2leads
6 Total Categories
CATEGORYLEADERvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
XXII3/4
Valuation MetricsMultiples, price ratios, and targets
—
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XXII3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ASBP6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
XXII leads this category, winning 3 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
XXII is the larger business by revenue, generating $10M annually — 5334.9x ASBP's $1,941. XXII is the more profitable business, keeping -65.7% of every revenue dollar as net income compared to ASBP's -16352.0%.
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $10M |
| EBITDAEarnings before interest/tax | -$28M | -$12M |
| Net IncomeAfter-tax profit | -$32M | -$7M |
| Free Cash FlowCash after capex | -$4M | -$15M |
| Gross MarginGross profit ÷ Revenue | +45.5% | -34.3% |
| Operating MarginEBIT ÷ Revenue | -10314.4% | -124.1% |
| Net MarginNet income ÷ Revenue | -16352.0% | -65.7% |
| FCF MarginFCF ÷ Revenue | -1811.5% | -144.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +59.5% |
| EPS Growth (YoY)Latest quarter vs prior year | — | — |
XXII leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| Market CapShares × price | $9M | $621,210 |
| Enterprise ValueMkt cap + debt − cash | $10M | $5M |
| Trailing P/EPrice ÷ TTM EPS | -0.72x | — |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.05x |
| Price / BookPrice ÷ Book value/share | — | 0.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
Insufficient data to determine a leader in this category.
Profitability & Efficiency
XXII leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), XXII scores 6/9 vs ASBP's 2/9, reflecting solid financial health.
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| ROE (TTM)Return on equity | — | -79.2% |
| ROA (TTM)Return on assets | -13.2% | -27.8% |
| ROICReturn on invested capital | — | -148.2% |
| ROCEReturn on capital employed | — | -196.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 2.15x |
| Net DebtTotal debt minus cash | $1M | $4M |
| Cash & Equiv.Liquid assets | $3,633 | $4M |
| Total DebtShort + long-term debt | $1M | $9M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | -7.56x |
XXII leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ASBP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ASBP five years ago would be worth $162 today (with dividends reinvested), compared to $0 for XXII. Over the past 12 months, ASBP leads with a -49.7% total return vs XXII's -99.8%. The 3-year compound annual growth rate (CAGR) favors ASBP at -74.7% vs XXII's -99.0% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| YTD ReturnYear-to-date | +35.8% | -93.6% |
| 1-Year ReturnPast 12 months | -49.7% | -99.8% |
| 3-Year ReturnCumulative with dividends | -98.4% | -100.0% |
| 5-Year ReturnCumulative with dividends | -98.4% | -100.0% |
| 10-Year ReturnCumulative with dividends | -98.4% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -74.7% | -99.0% |
ASBP leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ASBP and XXII each lead in 1 of 2 comparable metrics.
Risk & Volatility
XXII is the less volatile stock with a 1.60 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASBP currently trades 7.6% from its 52-week high vs XXII's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.60x |
| 52-Week HighHighest price in past year | $2.45 | $483.00 |
| 52-Week LowLowest price in past year | $0.05 | $0.67 |
| % of 52W HighCurrent price vs 52-week peak | +7.6% | +0.2% |
| RSI (14)Momentum oscillator 0–100 | 30.3 | 14.6 |
| Avg Volume (50D)Average daily shares traded | 11.8M | 1.4M |
Evenly matched — ASBP and XXII each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
XXII is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | ASBPAspire Biopharma … | XXII22nd Century Grou… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +100.0% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $14.11 |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XXII leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ASBP leads in 1 (Total Returns). 1 tied.
Best Overall22nd Century Group, Inc. (XXII)Leads 2 of 6 categories
Loading custom metrics...
ASBP vs XXII: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — ASBP or XXII?
Over the past 5 years, Aspire Biopharma Holdings, Inc.
(ASBP) delivered a total return of -98. 4%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: ASBP returned -98. 4% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ASBP or XXII?
By beta (market sensitivity over 5 years), 22nd Century Group, Inc.
(XXII) is the lower-risk stock at 1. 60β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 9% more volatile than XXII relative to the S&P 500.
03Which has better profit margins — ASBP or XXII?
22nd Century Group, Inc.
(XXII) is the more profitable company, earning -127. 7% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps -127. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XXII leads at -117. 4% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ASBP leads at 45. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — ASBP or XXII?
In this comparison, XXII (100.
0% yield) pays a dividend. ASBP does not pay a meaningful dividend and should not be held primarily for income.
05Is ASBP or XXII better for a retirement portfolio?
For long-horizon retirement investors, 22nd Century Group, Inc.
(XXII) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (100. 0% yield). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XXII: -100. 0%, ASBP: -98. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between ASBP and XXII?
These companies operate in different sectors (ASBP (Healthcare) and XXII (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ASBP is a small-cap quality compounder stock; XXII is a small-cap income-oriented stock. XXII pays a dividend while ASBP does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
- Sector: Consumer Defensive
- Market Cap > $100B
- Revenue Growth > 29%
- Dividend Yield > 40.0%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.